CRSP

CRISPR Therapeutics AG

NasdaqHealthcareBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$00 buys
Total selling$2.38M1 sale
Net open-market−$2.38MBuying minus selling
Active insiders4Distinct reporting owners

CRSP transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Sakhamuri Sivakesava
Chief Technology Officer
CTO
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Sakhamuri Sivakesava
Chief Technology Officer
CTO
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Kulkarni Samarth
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Kulkarni Samarth
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Patel Naimish
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Patel Naimish
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Silver Andrew Jacob
Chief Financial Officer
CFO
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
$0View disclosure →
Kulkarni Samarth
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Large disposal
Units disposed were at least 25% of reported post-transaction holdings.
Derivative securitySEC filing ↗
—View disclosure →
Kulkarni Samarth
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Cluster sell
At least two distinct reporting owners sold within 14 days, with combined known value of at least $100k.
Large sale
A sale above $1.0M, or above twice the company’s median insider trade with at least three prior trades in the sample.
+1
Repeat seller

The same owner reported more than one sale within 30 days.

SEC filing ↗
−$2.38MView disclosure →
Kulkarni Samarth
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
SEC filing ↗
—View disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Nov 6, 2026

Open-market transaction mix · 1 transactions in the selected period
0 buys0%·100%1 sells

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026015$0$2,381,325.86−$2,381,325.86
Nov 2026002$0$0$0

Distinct insiders active

Reporting-owner CIKs by month · peak Oct 2026 (3)
Oct 2026: 3 insidersNov 2026: 1 insiders
Oct 2026Nov 2026
4distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
4 insiders
Filing, role and holdings details
Recent filing activity
Most recent 6 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy—
Largest sale$2.38M
10b5-1 detected0
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
10transactionstxns
  • A · Grants / awards · dominant7 · 70%
  • M · Option exercise2 · 20%
  • S · Open-market sells1 · 10%

Activity by reported role

A joint filing can contribute to multiple roles
Chief executive officer5
CMO2
CTO2
Chief financial officer1

Reported Holdings After

Separated by insider, security, and ownership type

Kulkarni SamarthCommon Shares · Direct
360k312kOct 16, 2026Oct 19, 2026
311,899Oct 19, 2026
Kulkarni SamarthRestricted Stock Units · Direct
200k28.8kOct 16, 2026Oct 26, 2026
28,750Oct 26, 2026
Silver Andrew JacobRestricted Stock Units · Direct
25.0k25.0kOct 19, 2026Oct 19, 2026
25,000Oct 19, 2026
Patel NaimishStock Option (Right to Buy) · Direct
24.0k24.0kOct 26, 2026Oct 26, 2026
24,000Oct 26, 2026
Patel NaimishRestricted Stock Units · Direct
12.0k12.0kOct 26, 2026Oct 26, 2026
12,000Oct 26, 2026
Kulkarni SamarthStock Option (Right to Buy) · Direct
57.5k57.5kOct 26, 2026Oct 26, 2026
57,500Oct 26, 2026
Sakhamuri SivakesavaStock Option (Right to Buy) · Direct
90.0k90.0kNov 4, 2026Nov 4, 2026
90,000Nov 4, 2026
Sakhamuri SivakesavaRestricted Stock Units · Direct
40.0k40.0kNov 4, 2026Nov 4, 2026
40,000Nov 4, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
4 active days
Oct 16 → Nov 16
LessMore

CRISPR Therapeutics AG Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at CRISPR Therapeutics AG?

Sakhamuri Sivakesava, Kulkarni Samarth, Patel Naimish, Silver Andrew Jacob.

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

Kulkarni Samarth reported a sale on Oct 19, 2026 valued at $2.38M. Read the SEC filing.

What is the recent purchase and sale balance?

Net open-market selling in the selected period was $2,381,325.86. Sales can occur for many non-investment reasons.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.